Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: 613 who wrote (75355)	3/22/2002 10:43:16 AM
From: vds4	Read Replies (1) \| Respond to of 122087

that's twice you have said this 613. They do not have 4 drugs in phIII clinical trials. They have one drug "Genasense" involved in Phase III clinical trials. It is involved in three actually. from Genta's website Clinical Trials Phase 3 Trial in Chronic Lymphocytic Leukemia This randomized trial tests whether the addition of Genasense to standard treatment is superior to standard treatment alone. Standard treatment consists of cyclical treatment with a combination of two chemotherapy drugs, fludarabine and cyclophosphamide. The trial is limited to patients who have previously received and have relapsed from other therapies. Phase 3 Trial in Malignant Melanoma This randomized trial tests whether the addition of Genasense to standard treatment is superior to standard treatment alone. Standard treatment consists of a drug called dacarbazine (DTIC), which is administered once every 3 weeks. This trial is limited to patients with advanced-stage disease who have not previously received chemotherapy. (Prior vaccine or immunotherapy is allowed.) Phase 3 Trial in Multiple Myeloma This randomized trial tests whether the addition of Genasense to standard treatment is superior to standard treatment alone. Standard treatment consists of cyclical treatment with high-dose dexamethasone (a cortisone-like drug). The trial is limited to patients who have previously received and have relapsed from other therapies. Randomized Trial in Non-Small Cell Lung Cancer his randomized trial tests whether the addition of Genasense to a standard treatment is superior to standard treatment alone. Standard treatment in this trial is docetaxel (a taxane), which is administered once every 3 weeks. This trial is limited to patients with advanced disease who have been previously treated with one prior chemotherapy regimen. Phase 2 Trial in Acute Myeloid Leukemia This non-randomized trial tests whether the addition of Genasense to a newly approved standard treatment is superior to recent experience using the standard care alone. The accompanying drug in this trial is Mylotarg® (gemtuzumab ozogamicin), a monoclonal antibody conjugated with a toxin. The trial is limited to patients over the age of 60 who have relapsed from standard first-line chemotherapy. Phase 2 Trial in Chronic Lymphocytic Leukemia This non-randomized trial evaluates the safety and efficacy of Genasense as a single agent in patients with CLL. The trial is limited to patients who have previously received fludarabine in at least one of their prior therapies. Phase 2 Trial in Mantle Cell Lymphoma This non-randomized trial tests the single agent safety and activity of Genasense in patients with Mantle Cell Lymphoma. In addition, it will assess the safety and activity of Genasense in combination with R-CHOP (a combination of a monoclonal antibody with chemotherapy) for patients who do not respond to treatment with Genasense alone. Phase 2 Trial in Prostate This non-randomized trial tests whether the addition of Genasense to a standard treatment is superior to recent experience using the standard treatment alone. The standard drug in this trial is docetaxel (a taxane), which is administered once every 3 weeks. This trial is limited to hormone-refractory patients.